Episode 59: ASM Roundup - Day 2 with Dr. Marinka Twilt and Dr. Mo Osman

A groundbreaking session at the 2026 Canadian Rheumatology Association Annual Scientific Meeting revealed that B cells in lupus patients undergo measurable changes in distribution during flares—months before symptoms appear—suggesting a biological window for early intervention. This insight, from Dr. Carol Nasser’s research, challenges the assumption that flares are purely subjective, offering a path to predict and prevent them. Meanwhile, a standout undergraduate presentation by Nathan Barrett identified Siglec-1 as a promising serological biomarker for pulmonary involvement in idiopathic inflammatory myopathies, with serum levels inversely correlating with lung function. The meeting also spotlighted practical clinical shifts: statin-induced myositis can persist long after discontinuation, making rechallenge dangerous, and the Dunlop-Dotridge lecture emphasized that IVIG and rituximab should be first-line treatments, not steroids. A heated debate concluded that tapering DMARDs to a minimal effective dose—rather than stopping entirely—is safer and more sustainable, especially in patients with seropositive or unstable disease. These findings collectively point to a new era of precision rheumatology: earlier detection, smarter treatment sequencing, and patient-centered decision-making grounded in biology, not just symptoms.